1. Introduction {#sec1}
===============

Glaucoma is a pathological eye condition that is usually associated with an elevated intraocular pressure (IOP), and it is the second cause of blindness worldwide that it is currently named as the silent blinder.^[@ref1]^ Several attempts have been made in order to deliver antiglaucomatous drugs and increase their residence and contact with the cornea and to augment their penetration abilities. Among these attempts are the usage of particulate systems which include the lipid-based particles such as the liposomal vesicles,^[@ref2],[@ref3]^ solid lipid nanoparticles,^[@ref4]^ and nanostructured lipid carriers^[@ref5]^ on one hand and the utilization of other nonlipid particles such as the polymeric,^[@ref6]^ protein-based particles like gelatin-based particles^[@ref7]^ and surfactant-based counterparts such as the niosomes^[@ref8]^ on the other hand. These carriers were highly variable according to their size, encountering both micron- and nanosized particles throughout the investigated research articles.

Meta-analysis is an advanced statistical technique that combines data emerging from multiple studies on a particular topic. It increases the accuracy and precision of the study estimates. Actually, meta-analyses play fundamental roles in evidence-based healthcare-related topics. Compared to other study designs (such as randomized controlled trials or cohort studies), meta-analysis comes in at the top of the "levels of evidence" pyramid.^[@ref9]^

Currently, the use of meta-analysis is gaining more grounds and is considered crucial in both clinical and industrial decision-making,^[@ref10]^ though not fully explored in the drug delivery discipline. Additionally, with the advent of the Internet and computer softwares, the exploitation of literature and data is becoming easier and the mining of this treasure is becoming more warranted.^[@ref11]−[@ref13]^ Meta-analysis, the quantitative synthesis of information from independent sources (studies), forms a cornerstone of evidence-based medicine.^[@ref14]^ It is indeed a powerful tool that can be used to compare any intervention with a control.^[@ref10]^

The aim of this study was to provide a quantitative summary of the existing literature which utilized the particulate systems approach for the enhancement of the pharmacodynamics of glaucoma treatments represented by the area under effect (intraocular pressure, IOP) curve (AUEC), which is additionally considered an indirect marker of the bioavailability of the delivered drugs. The significance of this approach was assessed. Furthermore, two covariates were evaluated, namely, the type of material used (whether lipid-based or not) and the size of the particulate system (whether micronized or nanosized). Such information could be very helpful and insightful for the drug delivery and formulation scientists who wish to adopt this kind of approach to increase the efficacy of glaucoma therapy.

2. Results and Discussion {#sec2}
=========================

[Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} shows the summary of the performed meta-analysis study after calculating the standardized mean difference (SMD) for each study and the lower and upper confidence intervals (CIs). All the investigated studies were proven significant with CIs always lying on one side of the zero as a cutoff (i.e., either both positive or both negative) as demonstrated by the generated forest plot from the used software ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}). Usually, an individual study is considered significant if its SMD with its two CIs are all positive or all negative without crossing or passing the zero cutoff (i.e., in the current analysis, the particulate treatment significantly increases the AUEC or significantly decreases it as compared to the control, the drug solution).^[@ref10]^

![Overall forest plot of the investigated studies.](ao9b02895_0001){#fig1}

###### Summary of the Meta-Analysis of the Published Studies Investigating the Pharmacodynamic Effects of Antiglaucomatous Drug Particulate Systems

  study                                                      year   number of animals receiving the particulate system (Gp A)   mean AUEC of Gp A   SD of Gp A   number of animals receiving the drug solution (Gp B)   mean AUEC of Gp B   SD of Gp B   SMD       lower CI   upper CI   type of material[a](#t1fn1){ref-type="table-fn"}   size of particulate system[b](#t1fn2){ref-type="table-fn"}
  ---------------------------------------------------------- ------ ----------------------------------------------------------- ------------------- ------------ ------------------------------------------------------ ------------------- ------------ --------- ---------- ---------- -------------------------------------------------- ------------------------------------------------------------
  Naguib et al.^[@ref20]^                                    2017   6                                                           99.08               20.1         6                                                      11.78               1.54         5.651     3.123      8.18       1                                                  2
  Shokry et al.^[@ref21]^[c](#t1fn3){ref-type="table-fn"}    2018   6                                                           459                 10.76        6                                                      331.9               6.11         13.404    7.923      18.885     2                                                  1
  Shokry et al.^[@ref22]^[d](#t1fn4){ref-type="table-fn"}    2018   6                                                           455.1               5.43         6                                                      200.7               2.34         56.147    33.655     78.638     2                                                  1
  Hathout et al.^[@ref23]^[c](#t1fn3){ref-type="table-fn"}   2019   6                                                           567.6               15.12        6                                                      369.5               7.98         15.121    8.966      21.275     1                                                  2
  Hathout et al.^[@ref24]^[d](#t1fn4){ref-type="table-fn"}   2019   6                                                           528.8               13.27        6                                                      385.4               12.59        10.23     5.984      14.477     1                                                  2
  Youshia et al.^[@ref5]^                                    2012   3                                                           64.2                5.25         3                                                      10.9                1.83         10.817    4.491      17.144     1                                                  1
  Guinedi et al.^[@ref25]^                                   2005   6                                                           50.3                20.3         3                                                      3.5                 0.5          2.423     0.641      4.204      1                                                  2
  Eldeeb et al.^[@ref26]^                                    2019   7                                                           409.2               82.72        7                                                      81.46               10.44        5.203     3.009      7.396      2                                                  2
  Elmowafy et al.^[@ref27]^                                  2019   4                                                           106.7               29.09        4                                                      44.3                20.5         2.154     0.412      3.896      2                                                  2
  GómezGomez-Ballesteros et al.^[@ref28]^                    2019   6                                                           137.4               15           6                                                      58.9                18.8         4.259     2.214      6.305      1                                                  1
  Ibrahim e al.^[@ref29]^[e](#t1fn5){ref-type="table-fn"}    2015   5                                                           80.3                7.79         5                                                      25.94               0.91         8.848     4.777      12.919     2                                                  1
  Ibrahim et al.^[@ref30]^[f](#t1fn6){ref-type="table-fn"}   2015   5                                                           71.79               10.6         5                                                      25.95               0.91         5.501     2.79       8.211      2                                                  1
  Hassan et al.^[@ref31]^                                    2018   6                                                           759.7               16.7         6                                                      322.3               7            31.522    18.86      44.184     1                                                  1
  Bagav et al.^[@ref32]^                                     2011   3                                                           268.09              4.89         3                                                      38.4                4.21         40.166    17.384     62.948     2                                                  1
  Wang et al.^[@ref33]^                                      2014   6                                                           126.74              17.73        6                                                      171.17              16.45        --2.397   --3.881    --0.914    1                                                  1
  Hathout et al.^[@ref34]^                                   2007   6                                                           26.03               2.6          6                                                      7.825               2.34         6.792     3.848      9.735      1                                                  2

Type of material (lipid or nonlipid).

Size of particulate system (micro or nano).

5.5 g plunger of the tonometer.

10 g plunger of the tonometer.

Chitosan nanoparticles.

Alginate nanoparticles.

The overall meta-analysis study was extremely significant with a *P* value \< 0.001 with a pooled estimate of 7.987 and CI (5.334, 10.639), confirming the significance of the results and the presence of the real effect of the use of the particulate systems on the pharmacodynamic responses of the investigated drugs, as revealed by AUEC.

The particulate systems are usually successfully uptaken by the cells present in the different biological membranes such as the cornea that normally consists of stratified squamous epithelium (the hardest-to-penetrate) using different mechanisms such as passive diffusion, clathrate--claveolate-mediated endocytosis, and micropinocytosis.^[@ref15]−[@ref18]^

In another encounter, the heterogeneity of meta-analysis was high, with the degree of heterogeneity (*I*^2^) scoring 91%. The source of heterogeneity comes from the different years of study, different animals, different kinds of measurements, different climates, and different number of animals.^[@ref19]^

Additionally, a leave-one-out meta-analysis was carried out to exclude the study of the highest weight ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}) Wang et al. 2014. The pooled estimate changed to 7.940 (5.670, 10.210), and the heterogeneity dropped to 85% ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}).

![Leave-one-out meta-analysis forest plot of the investigated studies.](ao9b02895_0002){#fig2}

###### Investigated Study Weights

  study names                 weights (%)
  --------------------------- -------------
  Naguib et al. 2017          7.78
  Shokry et al. 5.5 g 2018    6.167
  Shokry et al. 10 g 2018     1.193
  Hathout et al. 5.5 g 2019   5.771
  Hathout et al. 10 g 2019    6.893
  Youshia et al. 2012         5.671
  Guinedi et al. 2005         8.067
  ElDeeb et al. 2019          7.918
  ElMowafy et al. 2019        8.08
  Ballesteros et al. 2019     7.975
  Ibrahim e al. CS 2015       6.993
  Ibrahim et al. Alg 2015     7.699
  Hassan et al. 2018          2.879
  Bagav et al. 2011           1.167
  Wang et al. 2014            8.158
  Hathout et al. 2007         7.589

Further exploring, the investigated studies were subdivided into two groups according to the main material used to fabricate the particulate system: subgroup 1----lipid-based encoded (1) and subgroup 2----nonlipid-based encoded (2). Subgroup meta-analysis was implemented, where subgroup 1 scored a pooled estimate of 8.266 with CIs (5.209, 11.322), whereas subgroup 2 scored a pooled estimate of 9.166 with CIs (4.927, 13.405). The overlapping CIs indicate nonsignificant differences between the two subgroups. Surprisingly, the lipid-based particulate systems were not superior to the nonlipid counterparts. Though lipids such as the phospholipids or triglycerides are compatible with the endothelial corneal layers, the surfactant-based particles are still compatible as usually nonionic surfactants are the ones used for ocular delivery. Additionally, even the polymeric and protein-based particles are still highly compatible with other corneal layers such as the stroma.^[@ref35],[@ref36]^

Moreover, the investigated studies were subdivided into two other subgroups according to the size range of the used particulate system: subgroup 1----nanosized particles encoded (1) and subgroup 2----micron-sized particles encoded (2). The subgroup meta-analysis was reimplemented changing the covariate. Subgroup 1 was proven significantly superior in increasing the AUEC as compared to the control, scoring a pooled estimate of 13.649 with CIs (8.462, 18.837), whereas subgroup 2 scored 5.906 with CIs (6.007, 10.712). The results are significant as the CIs do not overlap.

Although one may think that the micronized particles may reside in the cul-du-sac and in more contact with the cornea because of their larger particle size preventing their easy drainage, it seems that the higher penetration ability of the nanoparticles supersedes this property and enables the drugs to surpass the corneal barrier more efficiently.^[@ref35]^

3. Conclusions {#sec3}
==============

There is a strong literature-driven evidence based on meta-analysis that the particulate systems (micro/nano) potentiate the pharmacodynamic effects of antiglaucomatous drugs on animals. Furthermore, the study gives evidence that the nanoparticles are more efficient in lowering the IOP than the micronized counterparts and hence pose more efficient glaucoma therapies. The material with which the nanosystem is produced does not appear to influence its eye performance.

4. Methodology {#sec4}
==============

4.1. Data Mining {#sec4.1}
----------------

A computer-based search was conducted on databases such as Medlineand Embase and on a search engine, Google Scholar. SciFinder was also used to reconduct a further computer-based research for any relevant patents or commentaries.

The following keywords were utilized in the search: micro, nano, vesicles, lipid, polymer, polymeric, nanoparticles, glaucoma, ocular, and liposomes. All the searches were performed in English language.

4.2. Inclusion Data and their Criteria {#sec4.2}
--------------------------------------

The mined articles were considered eligible for evaluation if they contained the methodology and discussion related to particulate systems that are used as carriers for drugs to lower the IOP on animal studies through the topical ocular route. All initially eligible articles were further screened in detail by analyzing the abstract and full text. All the articles should contain original data (research articles). AUC or AUEC (starting from the baseline) should have been reported or can be calculated from IOP tables. The optimization or the formulation scoring the highest AUEC was selected in case of the studies containing several formulations.

The following data were collected from articles fulfilling the inclusion criteria: the name of the author and year of publication, the studied drug, type of the carrier (lipid-based or nonlipid-based: surfactants or polymers), particle size (micron or nano), and AUEC as a pharmacodynamic parameter compared to a control (drug solution).

4.3. Meta-Analysis {#sec4.3}
------------------

The meta-analysis was performed to confirm the augmentation of the pharmacodynamic effects of the antiglaucomatous drugs compared to the drug solution as a control, as revealed by AUEC, and this was considered the basis of the effect size of the experiment. As meta-analysis combines the results of different studies and gives an overall conclusion, "heterogeneity" should be considered.

The effect size (AUEC) and the study sample size were fed into OpenMetaAnalyst (<http://www.cebm.brown.edu/openMeta/>) to perform meta-analysis of the investigated studies and provide forest plots.

As the studies in this meta-analysis are variable in their animal numbers (sample size), they do not meet the underlying assumption of a fixed effect model that only the sampling error is the source of variability; hence, the overall effect size was estimated using the random effects model and utilizing the Der Simonian--Laird method. The random effects model takes into account the variability between studies such as measurements and sample size and was therefore claimed adequate for the purpose of this meta-analysis. Heterogeneity was assessed using two parameters: the *Q* statistic and the *I*^2^ index. The *Q* statistic gives an indication of the presence or absence of heterogeneity among a set of studies related to differences in the measurements, year of study, and conditions, whereas the *I*^2^ index gives an indication of the degree of heterogeneity. The mean percent increase and a 95% confidence interval (CI) was calculated and represented in the forest plot. Significance was employed by the *P* value. The sensitivity and consistency of the study were evaluated using the leave-one-out meta-analysis.

The effect size was calculated as followswhere *N* is the sample size (number of animals).

SMD was calculated aswherewhere *n*~a~ is the number of animals that received the particulate formulation, *n*~b~ is the number of animals that received the drug solution as a control, *S*~a~ is the standard deviation of the particulate formulation mean effect, whereas *S*~b~ is the standard deviation of the drug solution mean effect.

Every study weight was calculated as followswhere SE is the standard error of each study.

*Q* is the amount of observed heterogeneity that will be compared to the amount of expected heterogeneity by chance, whereas *I*^2^ index is the quantitative degree of heterogeneity and is calculated as: , where df is the degree of freedom taken as the number of studies -- 1.

Furthermore, the mined studies were divided into subgroups according to the following:(a)Particle type designed as covariate factors encoded (1) and (2) for lipid-based and nonlipid-based, respectively.(b)Particle size also designed as other covariate factors encoded (1) and (2) for the nano- and micron-sized particles, respectively.
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